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Involvement of Monocyte Subsets 
in the Immunopathology of Giant 
Cell Arteritis
Yannick van Sleen1, Qi Wang1, Kornelis S. M. van der Geest1, Johanna Westra1, Wayel H. 
Abdulahad1, Peter Heeringa  2, Annemieke M. H. Boots1 & Elisabeth Brouwer1
Monocytes/macrophages are critical in systemic and local inflammation in giant cell arteritis (GCA) and 
possibly in clinically overlapping polymyalgia rheumatica (PMR). Therefore, we aimed to understand the 
contribution of monocyte subsets and the CX3CR1-CX3CL1 and CCR2-CCL2 migratory pathways, to the 
pathology of GCA. Peripheral blood monocytes were enumerated in samples from newly-diagnosed, 
untreated GCA and PMR patients and after prednisone-induced remission. The distribution of classical 
(CD14brightCD16neg) and the more pro-inflammatory, intermediate (CD14brightCD16+) and non-classical 
(CD14dimCD16+) monocyte subsets was analysed by flow cytometry. The phenotype of macrophages 
in temporal artery biopsies (TABs) from GCA patients was studied by immunohistochemistry and 
immunofluorescence. A clear monocytosis was seen in newly diagnosed GCA and PMR patients 
caused by elevated numbers of classical monocytes. Prednisone treatment suppressed numbers of 
non-classical monocytes. Both chemokine CX3CL1 and CCL2 were highly expressed in the TAB. Most 
macrophages in the TAB of GCA patients expressed non-classical monocyte markers CD16 and CX3CR1 
whereas co-localisation of CD16 with classical monocyte marker CCR2 was infrequent. In conclusion, 
we report an altered distribution of monocyte subsets in both GCA and PMR patients. The majority of 
macrophages in TABs of GCA patients were CD68 + CD16 + CX3CR1 + CCR2− and thereby resembled 
the phenotype of non-classical monocytes.
Giant cell arteritis (GCA) is an immune mediated vasculitis characterized by granulomatous infiltrates in the 
vascular wall of medium and large arteries causing vascular occlusion leading to blindness or stroke. GCA is not 
solely a ‘’headache disease” (cranial GCA (C-GCA)) but can present with systemic vessel inflammation (large ves-
sel GCA (LV-GCA)). Both C-GCA and LV-GCA patients can have signs and symptoms of polymyalgia rheumat-
ica (PMR), which is characterized by pain and stiffness of both shoulders and hips and by systemic inflammation. 
PMR is observed in 50% of GCA patients and 15% of patients with PMR may develop GCA when left untreated. 
As GCA and PMR develop in persons over 50 years of age, with a median age of 70 at onset, it has been suggested 
that ageing-associated changes of the immune system may be involved1–3. Glucocorticoid treatment is currently 
the first choice for clinical management of GCA and PMR, but long-term glucocorticoid treatment is associated 
with severe side effects4. An improved understanding of the immunopathogenesis of GCA and PMR may eventu-
ally lead to highly needed alternative treatment options for GCA and PMR patients.
The immunopathogenesis of both GCA and PMR is not yet well understood. There is consensus, however, 
that GCA pathology is initiated by local dendritic cell activation followed by infiltration of the vessel wall by 
CD4+ T-cells and monocytes/macrophages via the vaso vasorum5. Within the vessel wall, migrated monocytes/
macrophages produce pro-inflammatory cytokines and matrix metalloproteases causing severe vascular dam-
age. Monocytes, the precursors of tissue infiltrating macrophages, are phagocytes generated in the bone marrow 
from which they are released into the bloodstream where they circulate for several days6. Three monocyte sub-
sets can be distinguished by phenotypic and functional characteristics: classical monocytes (CD14brightCD16neg), 
intermediate monocytes (CD14brightCD16+) and non-classical monocytes (CD14dimCD16+)7. CD14brightCD16neg 
classical monocytes represent the most abundant subset in the peripheral blood whereas the pro-inflammatory 
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CD16+ subsets (both intermediate and non-classical) are less frequent8. CD16+ monocytes are the more mature 
cells compared to the classical monocytes; a developmental relationship has been established, and their numbers 
increase with age9. Importantly, increased proportions of CD16+ monocytes have been associated with numer-
ous vascular and inflammatory diseases like RA10, sarcoidosis11, 12, SLE8 and ANCA-associated vasculitis13, 14.
To study the contribution of monocytes/macrophages to the immunopathogenesis of GCA, it is crucial 
to understand the monocyte subsets as precursors of the tissue macrophages and their chemokine directed 
migration in this disease. Tissue migration of different monocyte subsets is determined by differential expres-
sion of chemokine receptors15. Classical monocytes show a marked CCR2brightCX3CR1dim expression whereas 
non-classical monocytes show CCR2negCX3CR1bright expression16. Also, CD16+ monocytes show an increased 
capacity to adhere to endothelial cells and thereby more readily migrate across the endothelium when compared 
to CD16neg monocytes17, 18. Migration of CD16+ monocytes is guided by fractalkine (CX3CL1) – CX3CR1 inter-
action and inhibition of this interaction reduces transmigration19, 20.
So far, the distribution of the three monocyte subsets in GCA and PMR patients has not been studied. 
Moreover, as CD16+ monocytes are pro-inflammatory and increase with age, we hypothesized that these mono-
cytes preferentially migrate to the vascular wall and contribute to GCA pathogenesis. We therefore studied mono-
cyte subset distribution in newly diagnosed GCA and PMR patients and effects of prednisone treatment on these 
subsets. Next, we assessed whether CD16 was expressed by macrophages in temporal artery biopsies (TABs) of 
GCA patients. Lastly, we investigated expression of defined chemokine receptors and their ligands in peripheral 
blood of GCA and PMR patients and in temporal arteries of GCA patients.
Results
Monocyte counts are elevated in newly diagnosed GCA and PMR patients. Numbers of circulat-
ing monocytes as determined in a standard hematology counter were higher in newly diagnosed GCA (nGCA) 
and newly diagnosed PMR (nPMR) patients compared to HC (Fig. 1 and Tables 1 and S1). In addition, we 
assessed the effects of glucocorticoids after 3 months on treatment. Treatment led to normalization of monocyte 
numbers in remission PMR patients (rPMR) but this was not the case for monocyte numbers in remission GCA 
(rGCA) patients.
Altered distribution of circulating monocyte subsets in GCA and PMR. As a clear monocytosis was 
observed in nGCA/nPMR, we next analysed the distribution of the three different monocyte populations defined 
by CD14 and CD16 expression (Fig. 2a). Our analysis revealed numerical increases of classical monocytes in 
nGCA and nPMR patients when compared to HC, whereas numbers of intermediate and non-classical mono-
cytes were largely comparable (Figs 2b and S1). The increase in classical monocytes led to proportional decreases 
of non-classical monocytes in both nGCA and nPMR patients, but did not alter intermediate type monocyte 
proportions (Figs 2a and S1). Glucocorticoid treatment reduced the numbers of all three monocyte subsets in 
rPMR patients (Fig. 2b). Interestingly, in rGCA patients, 3 months of glucocorticoid treatment reduced numbers 
of non-classical monocytes but had no effect on numbers of classical and intermediate monocytes. Thus, both 
nGCA and nPMR patients are characterized by higher numbers of classical monocytes leading to proportional 
Figure 1. Total monocyte counts are elevated in newly diagnosed GCA and PMR patients. Absolute numbers 
of monocytes in freshly drawn whole blood obtained from healthy controls (HC, n = 20), newly-diagnosed 
patients with GCA (nGCA; n = 21), PMR (nPMR; n = 19) and in follow-up samples from patients in remission 
after 3 months of treatment (rGCA; n = 14, rPMR; n = 15). Data are expressed as Tukey box and whisker plots. 
The bottom and top of the box represent the first and third quartiles, and the band inside the box represents 
the second quartile (the median). The whiskers represent the 1.5 interquartile range (IQR) of the lower and the 
upper quartiles. The outlier is plotted as a dot. The Mann-Whitney U test was used to compare each patient 
group with HC. Paired samples (e.g. nGCA vs rGCA and nPMR vs rPMR) were compared with the Wilcoxon 
signed rank test. P-values of less than 0.05 (2-tailed) were considered statistically significant. P values are 
indicated in the graph.
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reductions of non-classical monocytes. Remarkably, clinical remission in GCA patients was associated with a 
clear reduction of non-classical monocytes.
CD16+ macrophages are readily detected in GCA TABs. As monocytes are recruited from the blood 
to peripheral sites of inflammation, where they differentiate into macrophages, we next investigated the phe-
notype of tissue macrophages in TABs with findings diagnostic of GCA and evaluated expression of CD16 and 
of macrophage marker CD68 (Figs 3a and S2 for isotype control stainings). CD68 and CD16 were both abun-
dantly expressed within the infiltrates of the adventitia, media and intima layer of the vessel wall (Fig. 3b). CD16 
expression was found to overlap with macrophage-rich areas as evidenced by CD68 expression. Indeed, scores 
of CD16+ and CD68+ cells in adventitia, media and intima were positively correlated (Fig. 3c). To rule out an 
involvement of NK cells expressing CD16, we stained for CD56 and found this marker to be virtually absent in 
the vessel wall. To further confirm the co-localization of CD68 and CD16, double immunofluorescence staining 
was performed. Indeed, within infiltrated regions, substantial co-localization of CD16 and CD68 was found, 
confirming that the majority of macrophages in the vascular wall express CD16 (Fig. 3d).
Monocyte CCR2 and CX3CR1 expression in GCA and PMR patients. Recruitment of monocytes 
to tissues is driven by specific chemokine and chemokine receptor interactions. As the three different monocyte 
subsets can also be distinguished by differences in their chemokine receptor expression profiles, we assessed 
expression of CCR2 and CX3CR1 on classical, intermediate and non-classical monocytes. In accordance with 
previous studies21, classical monocytes demonstrated a high per cell expression (Mean Fluorescence Intensity) of 
CCR2 with low expression of CX3CR1, while non-classical monocytes demonstrated high per cell expression of 
CX3CR1 and a lack of CCR2 expression (Fig. 4a,b). Following glucocorticoid treatment, CX3CR1 expression was 
down-modulated by all monocyte subsets in rGCA and rPMR patients. In contrast, CCR2 expression by mono-
cyte subsets was not sensitive to glucocorticoid treatment (Fig. 4c,d).
Systemic expression of CCR2 and CX3CR1 ligands in GCA and PMR patients. Next, we assessed 
if serum levels of the relevant chemokines were altered in the patient groups (Supplementary Table S2). Systemic 
levels of CCL2 and CCL11, the CCR2 receptor ligands, were lower in nGCA patients but normalized after gluco-
corticoid treatment. A similar pattern was observed in PMR patients but this did not reach statistical significance. 
In contrast, levels of both the CX3CR1 receptor ligands CX3CL1 (fractalkine) and CCL26 were not altered in 
GCA and PMR patients when compared to HC. Glucocorticoid treatment upregulated serum levels of CX3CL1 
in rGCA patients.
Thus, our combined data show a down modulation of CX3CR1 expression by monocyte subsets and a con-
comitant increase of the soluble form of CX3CL1 in rGCA patients. Also, CCR2 expression by monocyte subsets 
was not altered in nGCA and nPMR patients when compared to HC (data not shown), but reduced levels of the 
CCR2 ligands were noted. The latter may be explained by high consumption/binding to increased numbers of 
circulating CCR2-positive monocytes in newly diagnosed GCA and PMR patients.
Expression of CCR2, CX3CR1 and their ligands in GCA TABs. Next, we investigated expression of 







Age (yr); Median (range) 71 (52–81) 75 (54–84) 72 (53–83)
Females (%) 73 70 75
GCA diagnosis: PET-CT/TAB/PET-
CT + TAB 11/5/6 NA NA
PMR diagnosis: PET-CT/Chuang/PET-
CT + Chuang 1/0/4 1/6/13 NA
Leukocytes (109/L); Median (Range) 9.2 (5.0–18.4) p < 0.0001
8.7 (4.5–14.4) 
p = 0.0011 6.0 (4.2–9.6)
Hb (mmol/l); Median (Range) 7.0 (5.5–8.5) p < 0.0001
7,5 (5.6–9.3) 
p < 0.0001 8,7 (7.2–9.9)
ESR (mm/h); Median (Range) 65 (31–118) p < 0.0001
52 (30–124) 
p < 0.0001 12 (2–30)
CRP (mg/l); Median (Range) 47 (11–138) p < 0.0001
44 (7–186) 
p < 0.0001 2 (2–5)
Table 1. Baseline characteristics of patients and controls in the peripheral blood study. Characteristics of newly 
diagnosed glucocorticoid/DMARD-free GCA (nGCA) and PMR patients (nPMR) and of healthy controls 
(HC). Five out of 22 GCA patients also had PMR. In 14 out of 20 PMR patients LV-GCA was excluded based on 
PET-CT. Importantly, the diagnosis of PMR did not change into GCA during a minimal follow-up of 6 months. 
The Kruskal-Wallis test was performed to compare data among the three study groups. The Mann-Whitney 
U test was used to compare each patient group with HC. P-values of less than 0.05 (2-tailed) were considered 
statistically significant. Yr = years. PET-CT = positron emission tomography-computed tomography. 
TAB = temporal artery biopsy. Hb = haemoglobin, ESR = erythrocyte sedimentation rate. CRP = C-reactive 
protein. NA = not applicable.
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score 3–4) of CX3CR1-positive cells were detected (Fig. 5a,b). CX3CR1-positive cells were clearly detected 
in macrophage-rich areas of adventitia, media and intima. Double staining for CD16 and CX3CR1 showed 
co-localization of these markers, although different patterns were observed (Fig. 5c). In contrast, only few to 
moderate numbers of CCR2-positive cells (median scores 2–3) were found in these same areas (Fig. 5a,b). Double 
staining for CD16 and CCR2 confirmed that CD16+ cells rarely co-localize with CCR2 (Fig. 5d).
Next, we analysed tissue expression of chemokines CCL2 and CX3CL1. Both in inflamed and non-inflamed 
TAB we detected expression of CCL2 and CX3CL1 by VSMCs (Figs 5e and S3). Quantification of CCL2 and 
CX3CL1 in inflamed temporal arteries demonstrated expression of both chemokine receptor ligands in all three 
vessel layers with highest expression in the media (Fig. 5e,f). Thus, the phenotype of tissue macrophages in GCA 
TABs (CD68 + CD16 + CX3CR1 + CCR2−) resembles the phenotype of the non-classical monocytes in blood.
Discussion
Monocytes/macrophages are critical contributors to inflammatory diseases. Improved understanding of the role 
of monocyte/macrophages in systemic and local inflammation as seen in GCA and the closely related PMR may 
provide a rational for novel, prednisone-sparing treatment strategies. Our studies revealed a clear monocytosis in 
newly diagnosed GCA and PMR patients which is consistent with the notion of inflammation-induced monocyte 
recruitment from the bone marrow as observed in other inflammatory diseases22, 23. When analysing the con-
tribution of the different monocyte subsets to the rise in total blood monocytes, we found numbers of classical 
monocytes to be substantially increased in both GCA and PMR patients. The increase in classical monocytes led 
to a relative decrease of non-classical monocytes in these patient groups. Interestingly, glucocorticoid treatment 
further suppressed non-classical monocytes in GCA and PMR.
The increase of classical monocytes in newly-diagnosed GCA and PMR is likely due to bone marrow produc-
tion of new monocytes in response to inflammation. Although all three monocyte subsets can be found in the 
bone marrow24, 25, monocyte recruitment from the bone marrow is mainly driven by the CCL2/CCR2 pathway 
which would explain preferential recruitment of classical monocytes expressing high levels of CCR226. In line 
with this, we found systemic CCL2 levels decreased in newly diagnosed GCA patients, suggesting binding of this 
ligand to increased numbers of classical monocytes. Glucocorticoid treatment normalized serum levels of CCL2. 
A similar pattern was observed in PMR patients.
Figure 2. Altered distribution of monocyte subsets in GCA and PMR. (a) Flow cytometry gating strategy based 
on CD14 and CD16 expression to distinguish classical (CD14brightCD16neg), intermediate (CD14brightCD16+) 
and non-classical (CD14dimCD16+) monocytes subsets (left panel). Flow cytometry dot plots showing 
representative samples (equal numbers of events) from a healthy control (HC), a newly diagnosed GCA 
patient (nGCA) and a newly diagnosed PMR patient (nPMR) (right panel). (b) Absolute numbers of classical, 
intermediate, and non-classical monocytes in HC (HC, n = 20), newly-diagnosed patients with GCA (nGCA; 
n = 21) and PMR (nPMR; n = 19) and in the follow-up samples of GCA (rGCA; n = 14) and PMR (rPMR; 
n = 15) patients in remission after 3 months of glucocorticoid treatment. Data are expressed as Tukey box and 
whisker plots. The bottom and top of the box represent the first and third quartiles, and the band inside the box 
represents the second quartile (the median). The whiskers represent the 1.5 IQR of the lower and the upper 
quartiles. Outliers are plotted as dots. The Kruskal-Wallis test was performed to compare data among study 
groups. The Mann-Whitney U test was used to compare each patient group with HC. Paired samples were 
compared with the Wilcoxon signed rank test. P-values of less than 0.05 (2-tailed) were considered statistically 
significant.
www.nature.com/scientificreports/
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Although monocytosis is a characteristic of many inflammatory diseases such as RA22, Crohn’s disease23 and 
sepsis27, several further studies in these indications report on elevated numbers or proportions of CD16+ mono-
cytes28–30. In contrast, we did not detect an increase in numbers and proportions of CD16+ monocytes in newly 
Figure 3. CD16+ cells co-localize with CD68+ macrophages in GCA temporal artery biopsies. (a) 
Immunohistochemical staining for CD68 and CD16 in a representative temporal artery biopsy (TAB) 
diagnostic of GCA. Note that consecutive sections of the same tissue were used in Figs 3 and 5. (b) Semi-
quantitive mean scores of CD68+ cells and CD16+ cells in inflammatory areas of GCA TABs (n = 16). Scores 
are given for the adventitia (Adv), media (Med, infiltrating cells only) and intima (Int). Data are presented 
as scatter plots. The horizontal line indicates the median. (c) Positive correlation between CD16 and CD68 
scores in intima, media and adventitia in inflammatory areas of GCA TABs (n = 16), as determined by 
Spearman’s rank correlation coefficient. Due to overlap in semi-quantitative scores not all 16 scores can be 
appreciated. (d) Single staining for CD68, CD16 and double staining for CD16 and CD68, respectively, from 
left to right in the inflammatory area of a TAB section. An example of a magnified merged picture is shown for 
clarity. Blue = DAPI staining of nuclei; Green (FITC) = CD16 expression, Red (AF555) = CD68 expression; a 
macrophage cytoplasmic granules marker.
www.nature.com/scientificreports/
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diagnosed GCA and PMR patients. Rather, a proportional decrease of non-classical monocytes particularly, was 
noted. This is remarkable as classical monocytes are expected to develop into intermediate and non-classical 
monocytes. The lack of an increase in non-classical monocytes could be due to blunted (cause unknown) dif-
ferentiation of intermediate monocytes to non-classical monocytes9, 31. M-CSF and GM-CSF are thought to be 
the most potent inducers of differentiation towards the non-classical phenotype12, 32, 33. Better understanding of 
M-CSF and GM-CSF signalling in GCA and PMR patients may elucidate whether differentiation to non-classical 
monocytes is blunted in GCA and PMR. Alternatively, a selective loss of non-classical monocytes through sponta-
neous apoptosis, to which the CD16+ monocytes are more susceptible34 may underlie the proportional decrease 
of non-classical monocytes, a notion to be further explored.
Previous studies on the role of non-classical monocytes in homeostasis and in inflammation have revealed 
that non-classical monocytes actively patrol the vascular endothelium and are preferentially found in the mar-
ginal pool35, 36. Indeed, non-classical monocytes demonstrate an increased capacity to adhere to endothelial cells 
by virtue of the adhesion-related CX3CR1 which binds to the membrane-bound form of fractalkine (CX3CL1) 
expressed by endothelial cells36, 37. In the resting state, they clear damaged cells and debris and in infection or 
inflammation they are thought to be important in resolution of inflammation. Yet, in several disease conditions, 
non-classical monocytes may aggravate disease, possibly due to their pro-inflammatory potential and following in 
situ reprogramming8, 28. More recently, Mukherjee et al. showed that untouched non-classical monocytes indeed 
become pro-inflammatory upon activation8, 38. In line with this, non-classical monocytes are potent producers 
of the pro-inflammatory cytokine IL-6, which is a key molecule in the immunopathogenesis of GCA and PMR39. 
Figure 4. Expression of CCR2 and CX3CR1 by monocyte subsets in peripheral blood of GCA and PMR 
patients and effects of glucocorticoid treatment. (a) Representative flow cytometry dot plots of CCR2 and 
CX3CR1 by classical, intermediate and non-classical monocytes in a GCA patient. (b) Mean fluoresecence 
intensity (MFI) of CCR2 and CX3CR1 on classical (Class), intermediate (Inter) and non-classical (Non-
Class) monocytes in newly diagnosed GCA patients (nGCA; n = 21). Data are expressed as Tukey box and 
whisker plots. The bottom and top of the box represent the first and third quartiles, and the band inside the 
box represents the second quartile (the median). The whiskers represent the 1.5 IQR of the lower and the 
upper quartiles. Outliers are plotted as dots. (c) Mean fluorescence intensity (MFI) of CCR2 and CX3CR1 (d) 
on classical, intermediate and non-classical monocytes in newly diagnosed GCA (nGCA; n = 21) and PMR 
(nPMR; n = 20) patients and in the follow-up samples of GCA (rGCA; n = 15) and PMR (rPMR; n = 14) 
patients in remission after 3 months of glucocorticoid treatment. Data are expressed as dot plots linking 
individual paired data. The Wilcoxon signed rank test was used to compare paired samples. P values are 
indicated in the graph.
www.nature.com/scientificreports/
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Indeed, elevated levels of IL-6 are found in the serum of newly diagnosed patients5, 40. Taken together, the rela-
tive decrease of non-classical monocytes in GCA and PMR may be explained by an enhanced accumulation of 
non-classical monocytes in the marginal pool35, thereby facilitating preferential migration of non-classical mono-
cytes to sites of inflammation in GCA and PMR. The latter notion was studied here in GCA TABs only.
We are the first to describe a massive accumulation of CD16+ macrophages in TAB of GCA patients. CD16+ 
macrophages were found in all layers of the vascular wall. As the adventitia is considered to be the site of primary 
immunological activation in GCA41, this transmural inflammation is likely achieved following entry via the vasa 
vasorum in the adventitial layer, progressing to the medial and intimal layers of the vascular wall. Accumulation 
of CX3CR1 + CD16+ macrophages, rarely co-localizing with CCR2, indicates that most of the macrophages in 
the GCA TAB resemble the phenotype of non-classical monocytes in blood. Still, we cannot exclude the possi-
bility that both CD16 and CX3CR1 expression can be acquired after migration of classical monocytes to tissue. 
Figure 5. Expression of CCR2, CX3CR1 and their ligands in GCA temporal artery biopsies. (a) 
Immunohistochemical (IHC) staining for CCR2 and CX3CR1 in a representative temporal artery biopsy 
diagnostic of GCA. Note that consecutive sections of the same tissue were used in Figs 3 and 5. (b) Semi-
quantitive score of CCR2-, CX3CR1-postive cells in the inflammatory area of GCA TAB (n = 15 and n = 16, 
respectively). Intensity of staining was not taken into account. Scores are given for the adventitia (Adv), 
media (Med, infiltrating cells only) and intima (Int). Data are presented as Tukey box and whisker plots. The 
bottom and top of the box represent the first and third quartiles, and the band inside the box represents the 
second quartile (the median). The whiskers represent the 1.5 IQR of the lower and the upper quartiles. (c) 
Co-localization of CD16 and CX3CR1 in TAB from GCA patients. Single staining for CD16, CX3CR1 and 
double staining for CD16 and CX3CR1, respectively from left to right in the inflammatory area of a TAB 
section. Blue = DAPI staining of nuclei; Green(FITC) = CD16 expression, Red(AF555) = CX3CR1 expression. 
(d) CCR2 and CD16 rarely co-localize in TAB from GCA patients. Single staining for CD16, CCR2 and 
double staining for CD16 and CCR2, respectively from left to right in the inflammatory area of a TAB section. 
Blue = DAPI staining of nuclei; Green(FITC) = CD16 expression, Red(AF555) = CCR2 expression. (e) IHC 
staining for CCL2, CX3CL1 in a representative TAB. (f) Quantification of staining intensity (positive pixels/total 
number of pixels) of CCL2 and CX3CL1 in the inflammatory vessel wall (n = 16 for both markers). Data are 
presented as Tukey box and whisker plots. The bottom and top of the box represent the first and third quartiles, 
and the band inside the box represents the second quartile (the median). The whiskers represent the 1.5 IQR of 
the lower and the upper quartiles. Outliers are plotted as dots.
www.nature.com/scientificreports/
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Also, classical monocytes may gain CX3CR1 and lose CCR2 upon migration to tissue42. Thus, it remains to be 
established if non classical monocytes are the only precursors of tissue macrophages in GCA.
Previously, it was proposed that local proliferation of tissue-resident precursors may give rise to macrophage 
expansion at local sites rather than infiltration by monocytes43. We investigated this option but found that stain-
ing for the proliferation marker ki-67 was largely negative in TABs of GCA patients (data not shown), thereby 
excluding this notion.
The strong local expression of CX3CL1 in the GCA TAB is consistent with massive expression of CX3CR1. 
The presence of CD16+ monocytes in the tissue of GCA may thus be guided by the CX3CR1-CX3CL1 chemok-
ine axis. Although CCL2 is also expressed in lesions of temporal artery tissue, it seems that CCL2 is less impor-
tant for the migration of CD16+ monocytes. In early in vitro migration studies, it was noted that non-classical 
monocytes failed to migrate in response to CCL2, consistent with the absence of CCR2 on these cells44. It was 
also evidenced that in the absence of CCL2 action, i.e., in CCR2-/- mice, monocytes can still traffic into sites 
of infection26. Importantly, many studies described the importance for chemokine receptor CX3CR1 for tissue 
migration19, 45, 46.
Our study illustrated that glucocorticoid treatment led to clear reductions of non-classical monocyte counts in 
both GCA and PMR patients. Glucocorticoid treatment has been described to induce apoptosis of non-classical 
monocytes via a caspase-dependent mechanism47, 48. Selective glucocorticoid -induced apoptosis of non-classical 
monocytes may be explained by high expression of the glucocorticoid receptor in this monocyte subset47. 
Whether glucocorticoids also deplete the CD16+ macrophages in the GCA temporal artery, or in PMR synovial 
tissues, awaits further studies.
Glucocorticoid treatment led to clear reduction of CX3CR1 per cell expression by peripheral blood monocytes 
and an up regulation of serum CX3CL1. Thus, glucocorticoid treatment may have a dual effect. Induction of 
apoptosis on the one hand and reduced adhesion to endothelium by non-classical monocytes through suppres-
sion of CX3CR1 expression on the other hand; both effects will hamper the influx of new CD16+ monocytes to 
the tissue. Interestingly, we found a differential response of monocyte subsets to glucocorticoid treatment in PMR 
patients. All three subsets were down modulated in PMR patients in remission at 3 months. This is an unexpected 
finding as the accumulated glucocorticoid dose is substantially lower in PMR patients. An unexplored possibility 
is that classical monocytes in PMR are more sensitive to glucocorticoid treatment due to their altered character-
istics; a previous study showed an altered functionality of monocytes from PMR patients when compared with 
monocytes from GCA patients and controls49.
GCA and PMR are clinically closely related. Evidence for a common immunopathology, however, is lacking 
due to a paucity of histological data on TAB and synovial tissues obtained from PMR patients. Although our 
study showed similar changes in circulating monocyte subsets in both diseases, the local involvement of CD16+ 
monocytes/macrophages in PMR tissues remains to be established.
Other limitations, imposed by logistical constraints, involve the use of thawed PBMCs for the determination 
of monocyte subset numbers. Whole blood monocyte counts were established using a hematology counter and 
monocyte subsets were analysed on a later date using thawed samples of liquid nitrogen stored PBMCs (isolated 
on the day of blood withdrawal). Percentages of monocyte subsets were related to the whole blood monocyte 
counts to calculate the numbers of the monocyte subsets. We cannot exclude differential loss of cells during 
PBMC isolation or due to the freezing/thawing procedure, although this would not be expected to differ between 
patients and controls.
We show an altered monocyte subset distribution in GCA and PMR with a relative decrease of non-classical 
monocytes. Moreover, macrophages in temporal arteries of GCA patients were found to resemble the phe-
notype of non-classical monocytes. The data can be taken to suggest that driven by the CX3CL1 chemok-
ine non-classical monocytes infiltrate the arterial wall and develop into an inflammatory population of 
CD68 + CD16 + CX3CR1 + CCR2− macrophages in GCA. Glucocorticoids reduce the number of non-classical 
monocytes in blood and their expression of the CX3CR1 receptor, supporting a concept that the influx of new 
monocytes into the vessel wall is decreased by glucocorticoids leading to the eventual resolution of local inflam-
mation. New insights into the role of monocytes/macrophages in systemic and local inflammation as seen in 
GCA and the clinically overlapping PMR may provide a rational towards novel treatment strategies and help the 
identification of highly awaited, disease-specific biomarkers.
Materials and Methods
Study populations. Peripheral blood (PB) analysis: in a prospective study design, 42 patients who were 
newly diagnosed as having GCA (n = 22) or PMR (n = 20) were consecutively enrolled (Tables 1 and S1A,B). 
None of the patients were receiving glucocorticoids (prednisone) or disease-modifying anti-rheumatic drugs 
(DMARDs) at the time of blood withdrawal. Blood samples were obtained before noon and all donors were 
non-fasted. nGCA patients either had a positive TAB and/or positive 18F-fluorodeoxyglucose-positron emission 
tomography-computed tomography (FDG PET-CT). nPMR patients fulfilled the Chuang/Hunder criteria or 
showed a positive FDG PET-CT scan for PMR50. Diagnosis of the PMR patients did not change to GCA during 
a follow-up period of at least 6 months. As controls, we obtained blood samples from 24 age-matched, healthy 
controls (HC) who were screened for past or actual morbidities (Tables 1 and S1C).
We obtained 30 follow-up samples of GCA (n = 15) and PMR (n = 15) patients, who were in remission after 3 
months of prednisone treatment. Remission was defined as absence of clinical signs and symptoms and a normal 
erythrocyte sedimentation rate (ESR) (<30 mm/hr) and/ or c-reactive protein (CRP) <5 mg/L.
TAB immunohistochemistry study: TAB were obtained from a total of 16 biopsy positive GCA patients. Eight 
biopsy positive TAB were included from the 11 TAB available from the PB cohort. In addition, 8 nGCA patients 
who had a positive TAB were included in the study (Supplementary Table S1A).
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Written informed consent was obtained from all study participants. All procedures were in compliance 
with the declaration of Helsinki. The study was approved by the institutional review board of the UMCG 
(METc2012/375 for HC and METc2010/222 for GCA and PMR patients).
Patients treatment. GCA patients were initially treated with 40–60 mg/day (median dose; range 30–60) 
and PMR patients with 15–20 mg/day (median dose; range 10–40) of prednisone, respectively. Tapering of pred-
nisone treatment was started after 2–4 weeks, based on normalization of clinical signs and symptoms together 
with normalization of the ESR and/or CRP. After 3 months, the median prednisone dose was 25 mg/day (range 
15–50) in GCA patients and 15 mg/day (range 5–17.5) in PMR patients.
Flowcytometry. Absolute numbers of monocytes in freshly drawn PB samples were determined by BD 
MultiTest TruCount, as described by the manufacturer. Data were acquired on a FACS Canto-II (BD Biosciences) 
and analysed with FACSCanto Clinical Software (BD). PB mononuclear cells (PBMC) were isolated from fresh 
heparinized blood with Lymphoprep (Axis-Shield), frozen in medium with 10% DMSO/FCS, and stored in liquid 
Nitrogen for analysis at a later date. Thawed PBMCs were stained with the following mAb to quantify monocyte 
subsets and their chemokine receptor expression: CD3, CD14, CD16, CD19, CD56, CD66b, CCR2 and CX3CR1 
(Supplementary Table S3). Proper isotype controls were included. Cells were fixed and analysed using a LSR-II 
(BD) flowcytometer. Kaluza software (BD) was used for analysis. Classical (CD14brightCD16neg), intermediate 
(CD14brightCD16+) and non-classical (CD14dimCD16+) monocytes subsets were gated as previously described51.
Immunohistochemistry (IHC). TAB were obtained from 16 biopsy confirmed GCA patients 
(Supplementary Table S1A). The tissue was fixed in formalin and paraffin embedded. Tissue sections of 3 μm 
were deparaffinized and rehydrated. After antigen retrieval and endogenous peroxidase blocking, sections were 
incubated with anti-human primary antibodies detecting cellular markers CD16, CD68, CD56, CCR2 and 
CX3CR1 and the chemokines CCL2 and CX3CL1 (product information in Supplementary Table S4). Proper 
isotype controls were included. Next, slides were incubated with secondary antibody rabbit anti-mouse HRP 
(DAKO P0260) or goat anti-rabbit HRP (DAKO P0448). Following washing, slides were incubated with per-
oxidase (DAKO, Carpinteria, CA, USA, P0448 and DAKO P0260). After detection of peroxidase activity with 
3-amino-9-ethylcarbazole, slides were counterstained with haematoxylin. Since the temporal artery vessel walls 
of GCA contain skip lesions, detection of CD16-, CD68-, CD56-, CCR2-, CX3CR1- expressing cells (irrespective 
of intensity) in affected areas was semi-quantitatively scored on a five-point scale (0–4): 0 = no positive cells, 
1 = occasional positive cells (0–1% estimated positive), 2 = low numbers of positive cells (>1–20%), 3 = moder-
ate numbers of positive cells (>20–50%), 4 = high numbers of positive cells (more than 50%). Affected regions 
containing infiltrating cells were scored. Scoring was performed by two independent investigators, trained by a 
pathologist and average scores were calculated.
For quantification of tissue chemokine expression, stained sections were scanned using a Nanozoomer Digital 
Pathology Scanner (NDP Scan U10074–01, Hamamatsu Photonics K.K., Hamamatsu, Japan). Positivity of the 
staining was quantified (positive pixels/total number of pixels) for representative areas of the three vessel lay-
ers (total area >1 × 104 µm2) within infiltrated areas using software of Aperio ImageScope (V11.2.0.780 Aperio 
Technologies, CA, USA).
Immunofluorescence. To investigate if CD68 and CD16, CD16 and CX3CR1 or CD16 and CCR2 are 
co-expressed by cells in situ, double-labelling immunofluorescence stainings were performed. Formalin-fixed 
paraffin-embedded TAB tissue was deparaffinized and antigen retrieval was performed. Dilutions (1:50) of 
anti-CD68, anti-CD16, anti-CCR2, or anti-CX3CR1 antibodies were added and incubated overnight. Following 
washing, FITC-labelled goat anti-rabbit IgG (A11008, Lifetechnologies, Carlsbad, CA, USA) and AF555-labeled 
donkey anti-mouse IgG (A31570, Lifetechnologies) were used as the secondary antibodies, respectively. DAPI 
(10236276001, Roche Life Science, Penzberg, Upper Bavaria, Germany) was performed to stain nuclei. Images 
were taken using Leica DFC345 FX.
Serum chemokine measurements. Serum levels of CCL2 and CCL11 (ligands of CCR2) and CX3CL1 
and CCL26 (ligands of CX3CR1) were measured by Human premix Magnetic luminex screening assay kit 
(R&D system, Minneapolis, MN, USA) according to the manufacturers’ instructions. The assay was read by 
the Luminex LX100™ (Luminex, Austin, TX, USA) multiplex assay detection system. Raw data were analysed 
using Star Station V2.3. Lower and upper detection limits for the chemokine assays are 3–7936 pg/mL for CCL2, 
8–384218 pg/mL for CX3CL1, 2–5963 pg/mL for CCL26 and 8–30043 pg/mL for CCL11.
Statistical analysis. Since flowcytometry data and serum cytokine data are not normally distributed, 
non-parametric tests were used for data analysis. To compare data among more than two study groups the 
non-parametric Kruskal-Wallis test was performed. The Mann-Whitney U test was used to compare data of 
patient groups with HC. Paired samples (patients at diagnosis and after 3 months of treatment) were compared 
with the Wilcoxon signed rank test. Analyses were performed with GraphPad Prism 5.0 software. Correlations 
were assessed using Spearman’s rank correlation coefficient. P-values of less than 0.05 (2-tailed) were considered 
statistically significant.
Data availability. The datasets generated during and/or analyed during the current study are available from 
the corresponding author on reasonable request.
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